Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2024-11-06 Epub Date: 2024-09-26 DOI:10.1128/aac.00752-24

Anthony S Wasielewski, Anthony M Casapao, Christopher A Jankowski, Carmen L Isache, Malleswari Ravi, Ashlan J Kunz Coyne

引用次数: 0

Abstract

Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, P = 0.017).

查看原文本刊更多论文

肥胖对甲氧西林易感金黄色葡萄球菌血流感染临床结果的影响。

肥胖影响着三分之一以上的美国成年人，并使甲氧西林易感金黄色葡萄球菌（MSSA）血流感染（BSI）的治疗变得复杂。佛罗里达大学健康中心的一项研究比较了 233 名肥胖和非肥胖患者接受头孢唑啉治疗 MSSA BSI 的临床效果。在临床成功率（81.9% 对 82.7%）、死亡率（7.2% 对 5.3%）或不良事件（3.6% 对 3.3%）方面没有发现明显差异。不过，肥胖患者清除血液培养的时间更长（4.62 天 vs 4.01 天，P = 0.017）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.